🔹 Revenue: $6.54B (Est. $6.39B) 🟢 UP +2% YoY
🔹 Adj. EPS: $2.14 (Est. $2.15) 😐
🔹 BioTech Revenue: $1.87B (Est. $1.88B) 😐
🔹 Operating Cash Flow: $2.0B
🔹 Free Cash Flow: $1.5B
Q1 Guidance
🔹 Non-GAAP Core Revenue: Expected to decline low-single digits YoY
Full Year 2025 Guidance
🔹 Non-GAAP Core Revenue: Expected to grow ~3% YoY
Operational & Strategic Highlights:
🔹 Stronger Than Expected Finish: All three business segments exceeded internal expectations in Q4.
🔹 Portfolio Transformation: Danaher is now a focused life sciences & diagnostics innovator, driving long-term margin expansion and cash flow growth.
🔹 Execution & Efficiency: Strong operating margin expansion despite revenue softness in Biotech.
🔹 Strong Cash Flow: $6.7B in FY24 operating cash flow, positioning the company well for strategic investments.
CEO Commentary:
📌 "We finished the year strong, with better-than-anticipated core revenue across all segments. The transformation of our portfolio positions us for sustainable, higher growth and stronger cash flow in the years ahead." – Rainer M. Blair, CEO.
